RTP Mobile Logo
Beyond the Guidelines: Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Lymphoma and Chronic Lymphocytic Leukemia
Released March 2017

Proceedings from Part 1 of a 2-part satellite symposia series during the 58th ASH Annual Meeting. Featuring perspectives from Drs Brad S Kahl, John P Leonard, Gilles A Salles, Jeff Sharman, Julie M Vose and Michael E Williams. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia (CLL).

    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndrome, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Importantly, currently nearly 70 drug products are labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true within the realm of Hodgkin and non-Hodgkin lymphoma, where the past several years have yielded a staggering number of important clinical and research advances.

    Consensus-based guidelines aim to support oncologists and other cancer clinicians in making rational treatment recommendations, but in situations in which multiple “acceptable” therapeutic options exist, such guidelines may not be particularly helpful at the time of decision-making. Because these resources simply enumerate all diagnostic or treatment strategies supported by diverse levels of evidence rather than providing perspectives on the benefits and risks of one strategy versus another, they often leave the clinician alone to contemplate the optimal clinical approach. These proceedings from a CME symposium during the ASH Annual Meeting use an innovative strategy to formally document and present the perspectives, experiences and preferred treatment approaches of 30 lymphoma-specific investigators. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma, including CLL, with the formulation of up-to-date clinical management strategies.


    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering clinical presentation, biomarker profile and psychosocial status.
    • Appreciate the recent FDA approvals of several novel therapies for the treatment of newly diagnosed and R/R CLL, and discern how these therapies can be appropriately and safely integrated into routine clinical practice.
    • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R follicular, mantle cell and diffuse large B-cell lymphomas.
    • Assess the benefits and risks of evidence-based systemic treatment options to optimize the care of patients with peripheral T-cell lymphoma.
    • Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
    • Develop an understanding of the biologic rationale for and early efficacy and toxicity data with immunotherapeutic approaches for patients with various lymphoma subtypes.
    • Assess the ongoing clinical trials evaluating innovative investigational approaches for Hodgkin and non-Hodgkin lymphoma, including CLL, and obtain consent from appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHNHL17/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    St Louis, Missouri

    Advisory Committee: Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; Contracted Research: Abbott Laboratories.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cephalon Inc.

    Gilles A Salles, MD, PhD
    Professor of Medicine
    Université Claude Bernard
    Head of the Hematology Department
    Hospices Civils de Lyon
    Lyon, France

    Advisory Committee: Amgen Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Consulting Agreements: Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

    Jeff Sharman, MD
    Medical Director of Hematology Research
    The US Oncology Network
    Director of Research
    Willamette Valley Cancer Institute
    Eugene, Oregon

    Advisory Committee: Acerta Pharma, Celgene Corporation, Genentech BioOncology, Pfizer Inc; Consulting Agreements: Acerta Pharma, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Juno Therapeutics, Pfizer Inc; Contracted Research: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Merck, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Gilead Sciences Inc.

    Julie M Vose, MD, MBA
    Neumann M and Mildred E Harris Professor
    Chief, Division of Hematology/Oncology
    Nebraska Medical Center
    Omaha, Nebraska

    Contracted Research: Acerta Pharma, Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Janssen Biotech Inc, Kite Pharma, Seattle Genetics, US Biotest Inc.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia
    School of Medicine
    Charlottesville, Virginia

    Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Takeda Oncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.  

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2017
    Expiration date: March 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Dr Love: Introduction

Dr Kahl — Introduction

  • Chronic Lymphocytic Leukemia

Dr Kahl — Presentation

  • Chronic Lymphocytic Leukemia

Dr Kahl — Closing

  • Chronic Lymphocytic Leukemia

Dr Salles — Presentation

  • Follicular Lymphoma

Dr Salles — Closing

  • Follicular Lymphoma

Dr Sharman — Introduction

  • Hodgkin Lymphoma

Dr Sharman — Presentation

  • Hodgkin Lymphoma

Dr Leonard — Introduction

  • Mantle Cell Lymphoma

Dr Leonard — Presentation

  • Mantle Cell Lymphoma

Dr Williams — Introduction

  • Diffuse Large B-Cell Lymphoma

Dr Williams — Presentation

  • Diffuse Large B-Cell Lymphoma

Dr Vose — Presentation

  • T-Cell Lymphoma